Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 2/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | USP1 | O94782 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | USP8 | P40818 | 1/20 | 0.34 |
| ▸ | USP7 | Q93009 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7576242 | 0.81 | AR (0.44) | ESR2ARNSD2 | |
| SCHEMBL7570638 | 0.79 | CYP19A1 (0.49) | GABRG2GABRB3ESR2ARCYP19A1 | |
| SCHEMBL7569269 | 0.78 | CSNK2A2 (0.41) | ESR2ARCYP19A1PPARGPDE10A | |
| SCHEMBL7570331 | 0.77 | HTR7 (0.51) | AR | |
| SCHEMBL7572092 | 0.77 | CYP19A1 (0.56) | GABRG2GABRB3ESR2CYP19A1 | |
| SCHEMBL3901575 | 0.77 | GABRA1 (0.37) | GABRA1GABRG2GABRB3ESR2AR | |
| SCHEMBL7569476 | 0.75 | MCL1 (0.47) | — | |
| SCHEMBL7567116 | 0.75 | NSD2 (0.40) | ESR2ARCYP19A1NSD2 | |
| SCHEMBL7571007 | 0.74 | USP8 (0.37) | ESR2ARUSP1USP8USP7 | |
| SCHEMBL7569344 | 0.73 | SLC22A12 (0.39) | ESR2CYP19A1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | ABBOTT LABORATORIES | 2002-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019527-A1 | Substituted phenyl farnesyltransferase inhibitors | FNTA, FNTB, SLC10A1 | GABRA1 1921/4885GABRG2 2864/4885GABRB3 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.